Navigation Links
Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

headache (27%), vomiting (25%), peripheral edema (23%), rash (22%), diarrhea (22%), myalgia (19%), cough (19%), asthenia (18%), pruritus (17%), back pain (17%), anorexia (15%), arthralgia (14%) and upper respiratory tract infection (13%).

The percentage of patients reporting serious adverse events (SAEs) was higher for ONTAK than for placebo. Drug-related SAEs in ONTAK-treated patients were capillary leak syndrome (4%), dehydration (4%), hypotension (3%), fever (3%), hypoalbuminemia (2%), skin disorder (2%), chest pain (2%), vascular fragility (2%), fatigue (2%), hypersensitivity (2%), myocardial ischemia (1%), urinary tract infection (1%), blood pressure decreased (1%), joint stiffness (1%), myalgia (1%), carpel tunnel syndrome (1%), loss of consciousness (1%), respiratory distress (1%), dermatitis exfoliative (1%), erythema (1%), and rash generalized (1%). The frequency of SAEs decreased after the first two cycles of treatment. The percentage of patients overall who discontinued the study due to an adverse event was higher in the ONTAK group (20.0%) compared with the placebo group (9.1%).

"We are pleased that research continues with ONTAK in the treatment of patients with CTCL," said Judy Jones, Executive Director of the Cutaneous Lymphoma Foundation. "This study reflects Eisai's ongoing commitment to satisfying unmet medical needs in oncology, particularly in CTCL, a form of cancer for which there is no cure."

About ONTAK(R) (denileukin diftitox)

ONTAK is a genetically engineered fusion toxin protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, resulting in a molecule that is cytotoxic for cells bearing the target IL-2 receptor expressed on malignant cells.

ONTAK is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 recepto
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
5. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
6. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
11. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ("Sony") ... 8-well strip holder and 130um sorting chip.  Sony will also ... on its new SH800 Cell Sorter, the EC800 flow cytometer, ... tutorials at CYTO 2013, which will be held at the ... San Diego, California , from May 20 - ...
(Date:5/17/2013)... announced that it will report its 2013 first quarter earnings on Wednesday, ... Ed Borkowski , CFO, will host an analyst and investor ... participate in the conference call within the U.S. and Canada ... call outside the U.S. and Canada , dial (760) ... should dial in 10 minutes prior to the start of the call. ...
(Date:5/17/2013)... , May 17, 2013  PENTAX Medical, ... Hitachi-Aloka Medical, a global leader in ultrasound imaging, ... global companies to enable further innovation in the ... the Hitachi-Aloka ultrasound systems and PENTAX Medical endoscopic ... trusted families of EUS systems. This agreement will ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported ... announced the selection of its,disinfectant, EnviroTru(TM) for ... (Metro). EnviroTru(TM) is a multi-purpose disinfectant ... also meets EPA requirements for,Toxicity Category IV ...
... of statins treated for 3 months with 200 mg/week mipomersen experienced ... continues to support mipomersen,s ... safety profile,- Isis hosting Analyst & Investor Day today - webcast live at 9:00 ... at http://www.isispharm.com , ...
Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 2Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 4Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 5Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 6Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 7
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... 18, 2013) A ground-breaking advance in colonoscopy ... to research presented today at Digestive Disease Week ... withdrawal time for colonoscopies and exploring safer methods ... doctors use a device called a colonoscope to ... cancer allows a doctor to look for precancerous ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... Wright, KY (PRWEB) May 18, 2013 ... with hearing loss should consider the legal protections they ... claim, when problems arise with their child’s treatment or ... today. , Since 1927, the American Speech-Language-Hearing Association has ... communication disorders and to promote treatment, such as cochlear ...
(Date:5/18/2013)... Florida (PRWEB) May 18, 2013 Adolescents, ... also known as “Spice” or “K2” are landing in ... helping to curb this drug epidemic with a ... synthetic marijuana. , According to research from the National ... second-most popular illegal drug among American teenagers. In 2012, ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... may take her many steps forward in her career but is ... well known that stress influences eating pattern. A study conducted by ... to adopt certain unhealthy behavior upon working long hours, which can ... or consume too many snacks and may even go overboard on ...
... vocal cord dysfunction (VCD) – an involuntary functional disorder ... in a long-term study published in the current issue ... journal of the American College of Allergy, Asthma and ... and Pulmonary Division at the University of Iowa College ...
... be a wake up call to get the duvets washed and ... their duvets even in six months, and these could// be the ... ,A survey conducted in many households revealed that two ... months. The dust mites and filth are potential health hazards ...
... United Kingdom have lone inhabitants, which means there is a ... surely// an unhealthy trend, say Danish researchers, whose study has ... disease. ,The living alone and ill health ... the 30-69 age bracket. Their lives were studied in detail ...
... Queensland have been reviewed following allegations of inaccuracy by the ... Stephen Robertson there was an unusually low pickup of cancer ... ,9,300 cases were reviewed. Among these 83 women had ... non-malignant cancers. ,Two Gold Coast women are suing ...
... to a large-scale study published in the July issue of ... discontinued the use of Uprima// , a drug known to ... the success rates of this drug. ,And 70 ... an official National Health Service (NHS) drug feedback form felt ...
Cached Medicine News:Health News:Two Distinct Types of Vocal Cord Dysfunction Identified 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
AchilloTrain is a comfortable knitted support with a silicone insert alongside the Achilles tendon and under the heel. An additional heel cushion is provided for the unaffected foot. It is worn to tr...
DarcoGel™ Upper chamber is foam filled, conforms to calf; gel-filled lower chamber molds to the malleoli for a custom fit. Freeze the removable liner for cold therapy. One size. Fits left or ri...
... maintaining the ankle in functional alignment. Entire ... cushioning AliPlast™ foam liner. The cushioning air ... heel in a protective hammock, reducing ulceration ... bed from side-lying to supine. Only the ...
Medicine Products: